- Buzzwords
- serious infection,
- may be systemic
- immunocompromised
- Invasive Aspergillosis:
- A severe fungal infection caused by Aspergillus species.
- Primarily affects individuals with weakened immune systems,
- transplant recipients,
- chemotherapy patients, and those with
- HIV/AIDS.
- Also
- chronic obstructive pulmonary disease (COPD)
- Symptoms:
- Fever, often unresponsive to antibiotics.
- Chest pain.
- Cough with or without blood.
- Shortness of breath.
- Fatigue.
- DiagnosisCT scans
- Halo Sign:
- An early sign often seen in neutropenic patients.
- Presents as a central area of lung attenuation (ground-glass opacity) surrounded by a rim of ground glass.
- Indicates hemorrhage and edema around the infected area.
Halo Sign
-
- Nodules and Masses:
- As the infection progresses, nodules and masses can develop in the lung tissue.
-
-
- Irregular borders and variable enhancement patterns are typical.
- Nodules can cavitate, leading to the air crescent sign.
Air Crescent Sign
-
- Pneumonia
- Cavitation and Necrosis:
- Advanced invasive aspergillosis can lead to cavitation and necrosis of lung tissue.
- Cavities may contain fungal elements, blood, and debris.
Cavitation and Necrosis
- Angioinvasive Aspergillosis:
- subtype of invasive aspergillosis.
- refers to the tendency of the Aspergillus hyphae to
- invade and infiltrate blood vessels particularly the small
- causes
- vessel damage,
- thrombosis
- tissue infarction
Angioinvasive with Multiple Nodules in the Liver and Spleen
Angioinvasive Causing Splenic Infarction
Wedge Shaped Infarct in the Spleen
-
-
- Pleural Involvement:
- In severe cases, infection can extend to the pleura.
- Pleural effusion and pleural thickening may be observed.
- Distribution:
- Lesions are often multiple and can be bilateral.
- More commonly found in the upper lobes and periphery of the lungs.
- Laboratory tests including blood cultures and biomarker tests (such as galactomannan or β-D-glucan).
- Treatment:
- Antifungal medications (voriconazole, isavuconazole, or other options based on susceptibility).
- Intravenous therapy followed by oral treatment.
- Close monitoring of drug levels and potential interactions, especially in patients on multiple medications.
- Prognosis:
- Mortality rates can be high, especially in severely immunocompromised individuals.
- Early diagnosis and prompt treatment are critical for better outcomes.
- Prognosis improves if underlying immune issues can be addressed.
- Prevention:
- Minimizing exposure to environmental mold and fungi, especially in healthcare settings.
- Taking appropriate precautions for individuals with weakened immune systems.
- Timely administration of antifungal prophylaxis in high-risk patients.